Skip to content
lifestyle.marketresearchjournals.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Cognition Therapeutics, Inc.
Cognition Therapeutics Completes Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies with Psychosis
May 26, 2026
Cognition Therapeutics Receives Second Philanthropic Donation to Extend Ongoing Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies
May 24, 2026
Cognition Therapeutics Reports Financial Results for the First Quarter 2026 and Provides Business Update
May 24, 2026
Cognition Therapeutics Extends Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies
February 11, 2026
←
Previous Page
1
2